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Niemann–Pickdisease, typeC1 (NPC1) is a lipid storagedisorder
that results in progressive neurological impairment. The NPC1
phenotype is extremely variable and at the individual level is
likely influenced by other genetic traits. In addition to residual
function ofNPC1protein,we hypothesize thatmodifier genes, as
frequently observed with other autosomal recessive diseases,
influence the NPC phenotype. The NPC1 phenotype includes
progressive dementia, and the NPC pathology has some
overlap with the pathology of Alzheimer disease (AD). Thus,
we examined apolipoprotein E (ApoE) and microtubule-associ-
ated protein tau (MAPT) polymorphisms in a cohort of 15 NPC1
patients with well characterized longitudinal disease progres-
sion. Although we did not find any correlations between disease
severity and tau polymorphisms, we found significant associa-
tions between ApoE polymorphisms and phenotypic severity.
Specifically, ApoE4 and ApoE2 alleles were associated, respec-
tively, with increased and decreased disease severity in this
cohort of NPC1 patients. These data support the hypothesis
that ApoEmay play a role inmodulatingNPC1 neuropathology.
 2012 Wiley Periodicals, Inc.
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INTRODUCTION
Niemann–Pick disease, type C (NPC) is a lysosomal storage
disorder with a wide spectrum of clinical symptoms that are a
consequence of dysfunction of either the NPC1 or NPC2 protein.
Understanding the factors that contribute to this phenotypic
variation will provide insight into pathological mechanisms and
potential therapeutic interventions. NPC is caused bymutations of
either NPC1 or NPC2. To date, 244 NPC1 and 18 NPC2 mutant
alleles havebeen reported (http://npc.fzk.de/). Themajority ofNPC
cases, and the cases in this report, are due tomutation ofNPC1. The
NPC1 phenotype is variable in both age of neurological onset and
symptoms [Yanjanin et al., 2010]. Although there currently is no
goodassay toquantifyNPC1 function, it is likely that residualNPC1
function accounts for a large degree of this phenotypic variability.
However, residual NPC1 function does not explain phenotypic
variability within family and between individuals with the same
genotype [Lossos et al., 1997].Modifier genes frequently contribute
to the phenotype in autosomal recessive disorders. For example,
monoamine oxidase type B (MOAB) is a modifier gene in phenyl-
ketonuria [Ghozlan et al., 2004], and polymorphisms of both
mannose-binding lectin2 (MBL2) and transforming growth factor
beta 1 (TGFb1) influence pulmonary outcome in cystic fibrosis
[Accurso and Sontag, 2008]. This study was conducted to investi-
gate the impact of potential modifier genes on NPC severity.
Although NPC1 is a distinctly different disease than Alzheimer
disease (AD), common pathological processes may contribute to
both disorders. These include aberrant cholesterol metabolism
[Mann et al., 2004] and increased amyloid-b (Ab) [Yamaguchi
et al., 2001]. AD is pathologically characterized by amyloid plaques
and neurofibrillary tangles [Tiraboschi et al., 2004].Neurofibrillary
tangles are a common feature of NPC1, and their immunohisto-
chemical and ultrastructural appearances are identical to those
of neurofibrillary tangles in AD [Suzuki et al., 1995]. A major
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component of amyloid plaques in AD is Ab protein generated
due to aberrant processing of amyloid precursor protein (APP).
Consistent with overlapping pathological processes, abnormalAPP
processing has been observed in cultured NPC1 neurons [Jin et al.,
2004], and levels of Ab protein are significantly elevated in cerebral
spinal fluid from NPC1 patients [Mattsson et al., 2011]. Although
the characteristic amyloid plaques that are a cardinal finding in AD
are not observed inNPC, Saito et al. [2004] reported the presence of
diffuse plaques in 3/9 NPC patients. Of particular note, the ApoE
genotype for these three patients was ApoE4/ApoE4.
Based on the pathological overlap of NPC1 and ADwe explored
the hypothesis that the NPC1 phenotype could be modulated
by polymorphisms of apolipoprotein E (APOE) or microtubule-
associated protein tau (MAPT). APOE encodes a lipoprotein that
is highly expressed in the brain and plays a major role in central
nervous system cholesterol homeostasis [Han, 2004]. ApoE is
polymorphic with three major isoforms (ApoE2, ApoE3, and
ApoE4). These isoforms differ from each other only by a Cys to
Arg amino acid substitution at positions 112 or 158 [Zuo et al.,
2006]. ApoE3 accounts for approximately 64%of alleles [Eisenberg
et al., 2010], and is considered the ‘‘neutral’’ ApoEgenotype.ApoE4
is associatedwith increased risk of AD [Bignall, 1993] and impaired
cognitive function [Asada et al., 1996]. In contrast, ApoE2 may be
protective against AD in some populations [Tyrrell et al., 1998].
MAPT encodes a protein, tau, that promotes and stabilizes micro-
tubules [Weingarten et al., 1975]. TheMAPT haplotypeH1 is a risk
factor for AD [Shaw-Smith et al., 2006]. In this study, we correlated
ApoE and MAPT genotypes with neurological disease onset and
found that ApoE4 and ApoE2 alleles were associated, respectively,
with early and later neurological disease onset.
MATERIALS AND METHODS
Study Subjects
This study was approved by the Eunice Kennedy Shriver National
Institute of Child Health and Human Development Institutional
Review Board. DNA or cell lines were available for 15 of the 19
patients for whom longitudinal disease progression had previously
been characterized by chart review [Yanjanin et al., 2010]. DNA of
H12 was only available for APOE but not MAPT genotyping. To
determine the ‘‘age of neurological onset’’, the progression curve
derived from the total score was extrapolated to the x-axis (age) by
linear regression. Based on the calculated age of neurological onset,
patients were ordered from earliest to latest onset. A similar analysis
was also performed using the subset of the total score derived from
the memory and cognition subscores. Two of the patients had no
change in their subscores over multiple visits. H10, with an E3/E4
genotype, had a subscore of 3 stable from 10 to 18 years old; and
H12, with an E3/E3 genotype, had a subscore of 7 stable from 26 to
32 years old. In order to include these patients in the analysis,
we determined the mean (0.44 points/year) progression slope
for these two domains based on data from the other 13 patients.
We then used this value combined with the latest age for
which data were available to rank these patients. We felt that
this conservative estimate was more appropriate than exclusion
of these data.
APOE and MAPT Genotyping
APOE genotype was determined by PCR Restriction Fragment
Length Polymorphism (PCR-RFLP) assay using a previously
published protocolwithminormodifications [Hixson andVernier,
1990]. Briefly, PCR was used to amplify a 218 bp fragment of
genomic DNA which included APOE codons 112 and 158. The
PCR was carried out with the outer primer sequences (APOE-F:
50-CGGCTGTCCAAGGAGCTGC-30 and APOE-R: 50 GGCCT-
GGTACACTGCCAGG-30), amplifying a 218 bp DNA product.
The PCR was performed in a 50ml reaction mixture containing
100 ng gDNA, 50 pmol/ml primer, 10 RAB PCR buffer with
MgCl2þ (RocheApplied Science, Indianapolis, IN), 100mMdNTPs,
5U/L Taq polymerase, and 5MBetaine.One cycle of denaturation at
94C for 4min, was followed by 35 cycles at 94C for 45 sec, 64C for
45 sec, and72Cfor 45 sec.The reactionwas concludedwitha10min
extension step at 72C.Analiquot of the PCR-amplifiedproductwas
digested with restriction enzyme HhaI overnight at 37C. For
genotype analysis, the small fragment-sized cleavage products of
HhaI (48, 72, 81, and 91bp) were electrophoresed through 20%
polyacrylamide gels which were stained with ethidium bromide and
visualized with ultraviolet illumination.
MAPT genotype was determined by PCR amplification based
on a previously reported method [Baker et al., 1999]. The PCR
reaction utilized the forward primer sequence 50-GGAAGACGT-
TCTCACTGATCTG-30 and reverse primer 50-AGGAGTCTGG-
CTTCAGTCTCTC-30 to detect a 238 bp deletion in the H2
haplotype, yielding products of 484 or 245 bp for the H1 or H2
haplotype, respectively. The reaction was carried out in a 20ml
reactionmixture containing 50 ngDNAand final concentrations of
500 nM of each primer, 1X PCR buffer containing 1.5mMMgCl2,
250mMdNTPs, and 2U Taq polymerase (Roche). Denaturation at
95C for 4minwas followedby 35 cycles of 95C for 30 sec, 60C for
30 sec, and 72C for 45 sec; then an additional cycle of 95C for
30 sec, 50C for 30 sec, and 72C for 45 sec; and a final extension at
72C for 8min. PCR products were electrophoresed through 2%
agarose gels and visualized by ethidium bromide staining and
ultraviolet illumination.
Statistic Analysis
Statistical analysis was performed using Graph Pad Prism software
Version 5. The Mann–Whitney Test was used for statistical com-
parisons of ranked data. A nominal value of P< 0.05 was defined as
indicating a significant change. Error bars on graphs represent
standard error of the mean (SEM).
RESULTS
APOE genotyping was conducted on 15 DNA samples from
patients for whom longitudinal neurological progression had pre-
viously been characterized by chart review [Yanjanin et al., 2010].
This cohort of patients includes five females and 10 males, whose
severity score at initial evaluation range from1 to 27,with amean of
9 and a median of 7. Initial evaluation age of these patients
ranges from 1 to 38, with a mean of 14 and a median of 12. We
previously showed that disease progression was linear, and the rate
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of progression was independent of age in this group of patients.
Thus, to rank patients by onset we extrapolated the progression
curve to the x-axis. These values ranged from 0.5 to 35.5 years,
and we refer to this value as the calculated age of neurological
onset. The 15 NPC1 patients were ranked in order from earlier to
later neurological disease onset; and the number of patients with
childhood onset (0–12 years old), adolescent onset (13–18 years
old), and adult onset (>18 years old) were 10, 3, and 2, respectively.
APOE genotypewas determined by PCR-RFLP (Fig. 1A) andAPOE
genotypes for these 15 subjects are shown in Figure 2A. Of note,
ApoE4 and ApoE2 alleles are clustered in earlier and later onset
cases, respectively. Figure 2B compares the calculated age of
neurological onset for patients with and without an ApoE2 allele
and patients with and without an ApoE4 allele. NPC1 subjects with
an ApoE4 allele had a significantly earlier onset (3.6 0.8 years)
than those without an ApoE4 allele (15.5 3.64 years; P< 0.05),
and subjects with an ApoE2 allele had a significantly later onset
(19.3 0.8 years) than thosewithout anApoE2 allele (7.6 2.7 years,
P< 0.001).
Because memory and cognition are major issues characterizing
thedementia observed inNPC1,wealso ranked this cohort ofNPC1
patients based on the combined score of these two subscores
(Fig. 3A). In this method, NPC1 patients appear to have calculated
age of neurological onset ranging from7.5 to 33.2 years. Negative
values result from extrapolation to the x-axis and only represent
a tool to rank patients with regards to severity. Though not
statistically significant, we observed that patients with an ApoE4
allele and ApoE2 allele appeared to have a trend of earlier and later
onsets, respectively. Comparing the calculated age of onset values
utilizing the cognitive and memory subdomains (Fig. 3B), patients
with at least one ApoE4 allele had an earlier mean age of onset
(3.9 1.5years) compared to patients without an ApoE4 allele
(12.2 4.3 years). However, this was not significant (P¼ 0.09).
In contrast, patientswith anApoE2allelehada later calculated ageof
onset compared to patients without an ApoE2 allele (Fig. 3B)
(6.5 3.0 vs. 15.8 1.7 years, P¼ 0.07). MAPT genotyping for a
group of 14 NPC1 patients is shown in Figure 4. No significant
correlations between disease onset and MAPT genotype were
observed when ranking based on the total score (Fig. 4A) or the
memory and cognition subscore (Fig. 4B).
DISCUSSION
AD and NPC1 have some common pathological overlap including
increased levels of both Ab40 and Ab42, and the presence of
neurofibrillary tangles. The neurofibrillary tangles reported in
NPC are immunologically and ultrastructurally identical to those
observed inAD[Suzuki et al., 1995], andMattsson et al. [2011]have
recently shown that both Ab40 and Ab42 are abnormally increased
in CSF from patients with NPC1 disease.
ApoE4 is the most common genetic risk factor for AD [Bignall,
1993]. The mechanism by which ApoE4 increases the risk for AD is
not entirely understood [Verghese et al., 2011].However, a number
of pathologicalmechanisms, which alsomay influence pathological
progression of NPC1 disease, have been proposed. ApoE isoforms
differentially modulate amyloid b metabolism including produc-
tion and clearance, and thereby may contribute to Ab toxicity
[Huang et al., 2011; Verghese et al., 2011; Ye and Zhang, 2012].
ApoE isotype may influence other pathological mechanisms that
could play a role in bothNPC1 andAD.ApoE4 has been reported to
impair synaptic placticity [Chen et al., 2010], and ApoE isotype
appears to influence the development of neurofibrillary tangles
[Montine et al., 1999]. In this latter context, it is notable that Saito
et al. [2004] observed increased neurofibrillary tangles in brain
tissue from NPC patients who were homozygous for the ApoE4
allele. In this study we demonstrate a correlation between APOE
genotype and neurological disease onset in a 15-patient cohort of
NPC1 patients for whom we have both longitudinal disease pro-
gression data and DNA. Our observation that an ApoE4 allele is
associated with earlier neurological disease onset is consistent with
the pathological case series by Saito et al. [2004] that found that an
ApoE4 allele was associated with more severe neuropathological
findings. This observation is consistent with ApoE being amodifier
gene that contributes but does not determine to an earlier onset of
neurological symptoms inNPC1patients. Themajor determinate is
likely residual NPC1 function, and one would expect that other
genes also influence the pathology of NPC1 disease. A limitation of
bothof these studies is the small numberof cases.Unfortunately this
is a limitation that is inherent to the study of rare genetic diseases.
However, when combined, these studies suggest that ApoE may
play a role inmodulatingNPCneuropathology and that specifically
an ApoE4 allele may increase the severity of neurological disease in
NPC1. It will also be interesting to determine if ApoE genotype
FIG. 1. Apolipoprotein E (APOE) and microtubule-associated protein
tau (MAPT) genotyping. A: ApoE genotype was determined by
PCR/Restriction Fragment Length Polymorphism (PCR-RFLP)
analysis. ApoE alleles were identified by the DNA fragmentation
pattern (ApoE2: 67and91basepairs; ApoE3: 48and91basepairs;
ApoE4: 48 and 72 base pairs). B: MAPT genotype was determined
byPCR. H1andH2haplotypes correspond toDNA fragments of 484
base pairs and 245 base pairs, respectively.
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FIG. 2. Correlation of Apolipoprotein E genotype and neurological disease onset. A: NPC1 patients were ranked based on calculated age of neurological
onset and corresponding ApoE genotype is shown. ApoE genotypes including an ApoE4 allele are in red and those including an E2 allele are in green.
B: Significant differences in the calculated age of neurological onset were observed for NPC1 patients with and without an ApoE2 allele
(***P< 0.001) andNPC1patientswith andwithout an ApoE4allele (*P< 0.05). Calculated age of neurological disease onsetwasearlier for patients
with an ApoE4 allele and later for patients with an ApoE2 allele.
FIG. 3. Correlation of Apolipoprotein E genotype and onset of cognitive and memory deficits. A: NPC1 patients were ranked based on memory and
cognition scores. ApoE genotypes including an E4 allele are in red and those including an E2 allele are in green. *Rankingwas estimated for these two
subjects. B: NPC1subjectswith at least one ApoE2allele hada later age of onset compared to patientswithout an ApoE2allele, although this different
was not significant (P¼ 0.09). Similarly, mean age of onset was later in patients with at least one ApoE4 allele with a P-value of 0.07.
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contributes to the severity of cholestatic liver disease that is fre-
quently observed in the neonatal period. Although confirmation
will be required after longitudinal progression has been quantified
in larger cohorts of patients, identifying potential genetic modifiers
in NPC1 could provide immediate insight into pathological pro-
cesses that would be amendable to therapeutic intervention.
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